All Oncology News

MCARH109, a CAR T-cell therapy targeting the “enigmatic” GPRC5D antigen, generated remissions in 70.6% of patients with relapsed/refractory multiple myeloma.

Loncastuximab tesirine-lpyl combined with rituximab demonstrated encouraging antitumor activity and a feasible safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.

Momelotinib induced superior 24-week overall survival rates compared with danazol in thrombocytopenic, symptomatic, and anemic patients with myelofibrosis.

Study establishes rationale for combination approaches targeting multiple proteins — therapy produces responses in 70% of study participants, including those who who relapsed after prior CAR T therapy.

Single-agent rucaparib significantly improved radiographic progression-free survival vs chemotherapy or second-line androgen deprivation therapy in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer harboring BRCA or ATM mutations.

Early sensitivity to FGFR inhibition has improved outcomes for patients across tumor histologies; however, kinase domain mutations limit extended efficacy for select patients including those with intrahepatic cholangiocarcinoma or urothelial cancer.

Belantamab mafodotin plus lenalidomide and dexamethasone showed durable responses in patients with relapsed/refractory multiple myeloma.

The FDA has granted an accelerated approval to futibatinib (Lytgobi) for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.

As new mutational targets arise and genetic testing becomes more precise, the field of biliary tract cancer care may soon expand to accommodate a range of tailored treatments.

The combination of camrelizumab and nab-paclitaxel produced encouraging responses in patients with platinum-resistant, unresectable locally advanced or metastatic urothelial carcinoma.

Jaye Gardiner, PhD, a postdoctoral fellow at Fox Chase Cancer Center, was recently awarded the Merton Bernfield Memorial Award from the American Society for Cell Biology, making her one of 18 scientists from across the country to be recognized for their achievements in the life sciences.

Treatment with GB2064 monotherapy for at least 6 months led to a reduction in collagen fibrosis of the bone marrow of at least 1 grade in 4 of 5 evaluable patients with myelofibrosis, according to topline findings from a planned intermediate assessment of the phase 2a MYLOX-1 trial.

Treatment with rusfertide generated sustained hematocrit control at levels below 45% in patients with polycythemia vera, leading to a reduced need for repeated phlebotomy and eliminating this need in some patients, according to findings from 2 phase 2 clinical trials.

Investigators have set their sights on confirming the viability of HER3 as a clinically actionable therapeutic target for the treatment of patients with EGFR-mutant advanced non–small cell lung cancer, with the initiation of the phase 3 HERTHENA-Lung02 trial evaluating patritumab deruxtecan.

Ivosidenib plus azacitidine displayed favorable event-free survival, overall survival, and clinical responses compared with placebo plus azacitidine in patients with newly diagnosed, IDH1-mutated acute myeloid leukemia, according to findings from the phase 3 AGILE study.

E-selectin has emerged as a viable target in acute myeloid leukemia, and agents like uproleselan have the potential the increase AML cells’ sensitivity to chemotherapies such as cladribine plus low-dose cytarabine.

The FDA has approved the Oncomine Dx Target Test as a companion diagnostic to select patients with RET fusion–positive locally advanced or metastatic non–small cell lung cancer, advanced or metastatic thyroid cancer, and advanced or metastatic medullary thyroid cancer who could be candidates to receive selpercatinib.

The FDA has accepted for review a new drug application for 18F-rhPSMA-7.3, an investigational radiohybrid PSMA-targeted PET imaging agent for diagnostic imaging of prostate cancer, according to an announcement from Blue Earth Diagnostics.

Aumolertinib significantly prolonged progression-free survival vs gefitinib in treatment-naïve patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR mutations, according to findings from the phase 3 ANEAS trial published in the Journal of Clinical Oncology.

Scott M. Welford, Ph.D., is the new Tumor Biology Research Program co-leader at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

Outcomes from randomized phase 3 cancer trials are the foundation for regulatory approvals of novel antineoplastic therapeutics and, when available, treatment guidelines.

Nilay Shah, MD, discusses the importance of the FDA approval of sodium thiosulfate for pediatric patients with solid tumors, the favorable toxicity profile of the agent, and how clinical trial findings may inform future care in this population.

The FDA has granted an orphan drug designation to SynKIR-110, a first-in-class KIR-CAR T-cell immunotherapy candidate, for the treatment of patients with mesothelin-expressing mesothelioma.

Giredestrant provided a numerical, but not statistically significant, improvement in progression-free survival over physician’s choice of endocrine therapy in patients with estrogen receptor–positive, HER2-negative, locally advanced or metastatic breast cancer, according to data from the phase 2 acelERA BC study.

Chemoimmunotherapy combinations, along with therapies targeting IDH1, FGFR2, and HER2 mutations, are ushering in a new era of treatment for biliary tract cancers.

Gavocabtagene autoleucel demonstrated positive topline results from the phase 1 portion of a phase 1/2 trial in patients with mesothelin-expressing solid tumors.

NYU Langone Health has been recognized as No. 1 in quality and safety for inpatient and ambulatory care by Vizient, Inc.

The FDA has approved bevacizumab-adcd, a bevacizumab biosimilar, for the treatment of six types of cancer.

Vinorelbine plus cyclophosphamide and capecitabine led to a significant improvement in time to treatment failure compared with paclitaxel alone in patients with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer.

The addition of pyrotinib to trastuzumab and docetaxel significantly improved progression-free survival vs trastuzumab/docetaxel alone in patients with HER2-positive metastatic breast cancer.